MENU
ERAS
AS OF
Feb 3 closing price
Price
$10.59
Change
+$8.14 (+332.24%)
Capitalization
3.28B
43 days until earnings call
Intraday BUY SELL Signals
+Compare
ERAS
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$10.59
Change
+$8.14 (+332.24%)
Capitalization
3.28B

ERAS Erasca Forecast, Technical & Fundamental Analysis

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more

ERAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ERAS with price predictions
Feb 02, 2026

Momentum Indicator for ERAS turns positive, indicating new upward trend

ERAS saw its Momentum Indicator move above the 0 level on January 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on January 07, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 110 cases where ERAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ERAS broke above its upper Bollinger Band on January 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.416) is normal, around the industry mean (27.778). P/E Ratio (0.000) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.006).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ERAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ERAS is expected to report earnings to -10 cents per share on March 19

Erasca ERAS Stock Earnings Reports
Q4'25
Est.
$-0.11
Q3'25
Missed
by $0.01
Q2'25
Est.
$-0.12
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.02
The last earnings report on November 12 showed earnings per share of -10 cents, missing the estimate of -10 cents. With 5.67M shares outstanding, the current market capitalization sits at 3.28B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3115 Merryfield Row
Phone
+1 858 465-6511
Employees
126
Web
https://www.erasca.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BSCAX21.760.10
+0.46%
Brandes Small Cap Value A
DEVDX11.53N/A
N/A
Driehaus Event Driven
ARTMX33.09-0.11
-0.33%
Artisan Mid Cap Investor
VRSGX17.92-0.25
-1.38%
Virtus KAR Small-Cap Growth R6
JRARX82.09-1.75
-2.09%
Janus Henderson Research R

ERAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+0.95%
RVMD - ERAS
57%
Loosely correlated
+0.22%
ORIC - ERAS
48%
Loosely correlated
+8.77%
NUVL - ERAS
48%
Loosely correlated
+2.00%
ZNTL - ERAS
46%
Loosely correlated
+3.29%
CLDX - ERAS
42%
Loosely correlated
+0.24%
More